SAN FRANCISCO , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September: Baird Global Healthcare Conference : Uri Lopatin , MD, Chief Medical Officer, will

-  ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 -  Strong Balance Sheet Provides Significant Runway SAN FRANCISCO and INDIANAPOLIS , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.

INDIANAPOLIS and SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to ABI-H0731 for the treatment of patients with chronic Hepatitis B infection.

INDIANAPOLIS and SAN FRANCISCO , July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per share, which included

INDIANAPOLIS and SAN FRANCISCO , July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share.

INDIANAPOLIS and SAN FRANCISCO , July 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering.

Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) --   Assembly Biosciences, Inc.  (Nasdaq:ASMB), today announced the initiation of two multi-center,

Live event and webcast to focus on the potential of curative therapy for HBV infection and feature presentations from two liver medicine specialists INDIANAPOLIS and SAN FRANCISCO, June 13, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company

INDIANAPOLIS and SAN FRANCISCO , June 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for

INDIANAPOLIS and SAN FRANCISCO , June 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for